Single User License
INR 235970
Site License
INR 471940
Corporate User License
INR 707910

Service Tax Additional

select a format
Price

Single User License
USD 3500
Site License
USD 7000
Corporate User License
USD 10500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Pipeline Review, H2 2016

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Pipeline Review, H2 2016', provides in depth analysis on Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted pipeline therapeutics.

The report provides comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects

The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Overview 7

Therapeutics Development 8

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Products under Development by Stage of Development 8

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Products under Development by Therapy Area 9

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Products under Development by Indication 10

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Products under Development by Companies 13

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Products under Development by Universities/Institutes 15

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Companies Involved in Therapeutics Development 24

Bayer AG 24

Bristol-Myers Squibb Company 25

Ionis Pharmaceuticals, Inc. 26

LegoChem Biosciences, Inc 27

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Drug Profiles 28

AB-012-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

AB-022-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

BAY-1213790-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

BMS-262084-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

BMS-654457-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

coagulation factor XI (human)-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

coagulation factor XI (human)-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

EP-7041-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

IONIS-FXIRx-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Small Molecule 2 to Inhibit Factor XIa for Thrombosis-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Small Molecules to Inhibit Factor XIa for Cardiovascular-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Dormant Projects 43

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Featured News & Press Releases 44

Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis 44

Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022 44

Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 45

Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 46

May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 46

Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma 47

Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery 48

Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding 48

Feb 02, 2011: Isis Initiates Phase I Clinical Trial Of ISIS-FXIRx To Treat Clotting Disorders 50

Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders 50

Appendix 51

Methodology 51

Coverage 51

Secondary Research 51

Primary Research 51

Expert Panel Validation 51

Contact Us 51

Disclaimer 52

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 22

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by Bayer AG, H2 2016 24

Pipeline by Bristol-Myers Squibb Company, H2 2016 25

Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 26

Pipeline by LegoChem Biosciences, Inc, H2 2016 27

Dormant Projects, H2 2016 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bayer AG, Bristol-Myers Squibb Company, Ionis Pharmaceuticals, Inc., LegoChem Biosciences, Inc

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Therapeutic Products under Development, Key Players in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Therapeutics, Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Pipeline Overview, Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Pipeline, Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com